Oklo, Southwest, ASML, Axon, Centene: Trending by Analysts

Analysts are intrested in these 5 stocks: ( (OKLO) ), ( (LUV) ), ( (ASML) ), ( (AXON) ) and ( (CNC) ). Here is a breakdown of their recent ratings and the rationale behind them.

Oklo Inc. is making waves in the energy sector with its innovative small module reactor technology, which is based on proven fast fission reactor technology. Analyst Derek Soderberg has initiated coverage with a ‘Buy’ recommendation, citing Oklo’s potential to lead the multi-trillion-dollar grid expansion. The company’s reactors are highly scalable and ideal for the growing data center market, offering a significant total addressable market. With a favorable regulatory environment and the ability to use recycled nuclear fuel, Oklo’s long-term prospects look promising.

Southwest Airlines has seen its stock downgraded to ‘Hold’ by analyst Duane Pfennigwerth, following a period of outperformance. The airline is in the midst of implementing changes to improve its margins, but the stock’s valuation now appears closer to fair value. While Southwest’s aggressive share buyback program has contributed to its recent success, there are questions about its sustainability. The airline’s future growth may depend on its ability to offer more compelling services and capitalize on structural improvements in the industry.

ASML Holding has also been downgraded to ‘Hold’ by analyst Srini Pajjuri, despite a stable near-term outlook. The company’s revenue and earnings projections for 2025 and 2026 remain strong, but there is uncertainty around future bookings. ASML’s valuation is currently at a discount, which presents an attractive risk/reward scenario. The company is expected to benefit from growing demand for advanced logic and memory, although the impact of lower litho intensity remains a concern.

Axon Enterprise is recognized as an exceptional growth story, with analyst Andrew Spinola initiating coverage with a ‘Hold’ rating. The company’s strong growth prospects are already reflected in its stock price, which is why the risk/reward is seen as balanced. Axon’s US public safety business continues to drive growth, while its international and enterprise segments offer significant potential. However, the company is still in the early stages of ramping up these markets, and investors may be waiting for a better entry point.

Centene has been downgraded to ‘Sell’ by analyst Joanna Gajuk due to legislative reforms impacting its growth. The recent Reconciliation Bill is expected to slow growth in Medicaid and ACA exchanges, leading to lower earnings estimates for 2026 and 2027. The company’s visibility into its turnaround is limited, with new membership pressures and shifting risk pools adding to the challenges. As a result, Centene’s stock price objective has been reduced, reflecting the difficult environment it faces.